Notice of Results

RNS Number : 4675Y
Venture Life Group PLC
09 September 2015

Venture Life Group plc


("Venture Life" or "the Group")


Notice of Interim Results



Bracknell, UK - 9 September 2015: Venture Life Group plc (AIM: VLG), the international consumer products group addressing the self-care needs of the ageing population, will announce its Interim Results for the six months ended 30 June 2015 on Tuesday 29 September 2015.


- Ends -


For further information please contact:


Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer

+44 (0) 1344 742870

Panmure Gordon (UK) Limited

Freddy Crossley / Duncan Monteith

+44 (0) 20 7886 2500

Corporate Finance

Tom Salvesen

Corporate Broking

Square1 Consulting

David Bick / Mark Longson

+44 (0) 20 7929 5599



Notes to editors


About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.


Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors. The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

·     food supplements to maintain brain function and memory;

·     dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

·     medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.


The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

This information is provided by RNS
The company news service from the London Stock Exchange
UK 100

Latest directors dealings